Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130021/S188

Evolut FX Delivery Catheter System of the Evolut FX Transcatheter Aortic Valve System; Evolut FX+ Transcatheter Aorti

Medtronic, Inc. · Decision date Nov 7, 2026

MEDTECHLEDGER EXPLANATIONP130021/S188

What did the FDA decide?

FDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.

The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.

FDA approval order statement

the introduction of an automated vision system for the detection of flash
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Nov 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P130021/S188
Regulatory pathway
PMA supplement
Product code
NPT
Decision code
OK30
Decision date
Nov 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Aortic valve, prosthesis, percutaneously delivered.

Product code
NPT
FDA device class
3

For the original device and its historical approval scope, see PMA P130021. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P130021 · Original PMA

    MEDTRONIC COREVALVE SYSTEM

  2. P130021/S188 received

    Application receipt date recorded by FDA.

  3. P130021/S188 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P130021. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130021

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA approvalJan 17, 2014FDA

Explore the linked device profile

Other records with product code NPT

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
710 Medtronic Pkwy., Miinneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records